INTRODUCTION
Overall, chronic kidney disease (CKD) has declined in the combined antiretroviral therapy (cART) era owing to declines in human immunodeficiency virus (HIV)-associated renal disease [1] . However, because patients with HIV are now living longer [2] , CKD disease is proportionally becoming an increasingly important cause of morbidity [3] and mortality [4] in this population. The prevalence of moderate or severe renal impairment in patients with HIV infection, defined as a sustained decrease in the estimated glomerular filtration rate (eGFR) to\60 mL/min/1.73 m 2 for 3 months or more, ranges from 3.5 to 9.7% [5] , with rates of mild renal impairment (eGFR 60-90 mL/min/m 2 )
being as high as 34.2% [6] . The causes of CKD in patients with HIV have shifted away from HIV-associated nephropathy (HIVAN) [7] toward associated coinfections, such as hepatitis B and/or C [8] , behavioral risk factors, such as injecting drug use [9] or over-the-counter medication use [10] , and probably most importantly, background factors that also affect the general population, such as aging, hypertension, and diabetes [11] [12] [13] .
Despite the overall benefit of antiretroviral (ARV) therapy for the reduction of renal disease in HIV [14] , there is emerging concern that certain ARVs [15] , particularly tenofovir disoproxil fumarate (TDF) [16] with or without a boosted protease inhibitor (PI) [17] , may be associated with declines in renal function over time.
Although some individual PIs such as indinavir (IDV) are well known to cause acute kidney injury (AKI) [18] and CKD [19] , it is much less certain whether other PIs are associated with CKD either alone or in interaction with nucleoside/nucleotide reversetranscriptase inhibitors (NRTI/NtRTIs) such as TDF. The recent surge of low-quality evidence in the form of small cohort studies and/or case series reporting renal changes with PI use have contributed to added concerns and confusion as to how clinicians should respond.
There is also additional confusion as to the most appropriate methods to measure renal function in patients with HIV because the commonly used creatinine-based estimating equations for glomerular filtration rate can be biased in the context of HIV-related muscle wasting [20] .
There is, therefore, a need for clarity, based on a review of high-quality evidence. The aims of the current literature review were as follows: via a qualitative data synthesis, to critically evaluate evidence for changes in renal function over time with the currently used PIs such as atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV), when analyzed individually, or as a class effect, or in interaction with TDF coadministration.
METHODS
English language articles on randomized controlled trials (RCTs) and observational studies published over the last 10 years containing data on changes in renal function with the use of ATV, DRV, FPV, LPV, or SQV were critically evaluated. This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
Definition of Renal Toxicity as Evaluated in this Review
Articles were selected for review if they contained longitudinal data examining CKD as follows: (i) an increase in serum creatinine; and/ or (ii) a decrease in estimated creatinine clearance (eCC) as estimated by the CockcroftGault (CG) equation [21] ; and/or (iii) a decrease in eGFR as assessed by the Modification of Diet in Renal Disease (MDRD) [22] , MDRD-4 [23] , or Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) [24] estimating equations; and/or (iv) an increase in proteinuria or urinary albumin:creatinine ratio (ACR). In addition, we reported RCT discontinuation rates due to renal adverse events (AEs). Articles presenting data on AKI, HIVAN, tubulopathies, or nephrolithiasis were not selected.
In established guidelines from the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation CKD is defined as either kidney damage or decreased kidney function (decreased GFR\90 mL/min/ 1.73 m
2 ) for at least 3 months (Table 1 ) [25, 26] .
More recently, the Kidney Disease Improving
Global Outcomes (KDIGO) 2012 guidelines have introduced the concept of rapid progression, defined as a sustained decline in eGFR of more than 5 mL/min/1.73 m 2 /year [27] .
Specific issues relating to the measurement of renal function in patients with HIV-1 infection and the relative merits of estimating equations for creatinine clearance and GFR in this population are summarized in the online supplementary material section.
Other Inclusion and Exclusion Criteria
Further criteria for inclusion were as follows:
patients with HIV-1 infection; use of PI(s) that are currently recommended in established US and EU treatment guidelines as part of an ARV regimen, either evaluated alone or in comparison with regimens containing other ARVs; RCTs (both double-blind or open-label designs), observational studies, and metaanalyses; English language articles; and a publication date within the last 10 years up to and including August 12, 2013 . To reduce bias, observational studies were included only if they had recruited patients from more than one center and had analyzed data on at least 1,000
patients.
Further criteria for exclusion were as follows: if the abstract was unavailable; animal studies; case reports; presenting data in children and/or adolescents \18 years of age; if a conference abstract was superseded by journal publication; if no useable AEs not leading to discontinuation; if the article PDF was unavailable; pharmacokinetic studies; articles examining renal function as a predictor of other outcomes, renal function in ART-naïve patients, or renal function posttransplantation; and other review articles.
Search Strategy
The databases searched were Embase/Medline through the OVID platform and PubMed over the last 10 years up to and including August Adapted from Levey et al. [25] a Chronic kidney disease is defined as either kidney damage or GFR less than 60 mL/min/1.73 m 2 for 3 or more months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies. For stages 1 and 2, kidney damage is estimated using untimed urine samples to determine the albumin:creatinine ratios; greater than 17 mg/g in men or greater than 25 mg/g in women on two measurements indicates kidney damage b Glomerular filtration rate is estimated from serum creatinine measurements using the Modification of Diet in Renal Disease study equation based on age, sex, race, and calibration for serum creatinine c Prevalence for stage 5 is from the US Renal Data System (1998); it includes approximately 230,000 patients treated with dialysis and assumes 70,000 additional patients not receiving dialysis. Prevalence for stages 1-4 is from the Third National Health and Nutrition Examination Survey (1988) (1989) (1990) (1991) (1992) (1993) (1994) . Population of 177 million adults aged 20 or more years. GFR Glomerular filtration rate guidelines were also consulted for relevant information.
Because it was not always apparent on abstract screening whether data on PI use would be contained within the main body of the article, a two-stage screening process was adopted. First, abstracts were selected for fulltext retrieval according to the inclusion/ exclusion criteria, irrespective of whether PIs were mentioned in the title/abstract or not. Second, full-text articles were screened again according to the inclusion/exclusion criteria and were specifically excluded if they did not contain data on currently recommended PIs.
Data Synthesis
Selected articles were weighted according the Oxford Centre for Evidence-Based Medicine Levels of Evidence 1 Finally, the evidence obtained above was balanced against indices of study quality known to potentially bias reported outcomes according to established methods [16, [29] [30] [31] [32] .
RESULTS

Articles Selected
A summary of the article selection process is shown in the PRISMA flow diagram (Fig. 1 (Table 2 ). In contrast, serum creatinine was not elevated at 48 weeks with a regimen consisting of efavirenz (EFV)/FTC/TDF in a third RCT ( Table 2 ). Given that both COBI and to a lesser extent RTV inhibit the active tubular secretion of creatinine [35] , the changes in serum creatinine, eCC, and eGFR are a likely consequence of COBI and/or RTV components rather than a direct effect of ATV on kidney function. The rapid rise in serum creatinine Suggests that ATV/r interacts with TDF for a decline in renal function over time
Open-label Method for eCC not described 32% of patients discontinued third drug (ATV/r or EFV) Small sample size No numeric data provided to assess changes with ATV/r with or without TDF (Table 3B ) [44] .
In studies comparing LPV/r-containing regimens with non-PI-containing regimens, the effect of LPV/r on indices of renal function depended upon the presence or absence of TDF coadministration with LPV/r (Table 3C ). In the post hoc analysis from ACTG A5142, a multivariate analysis showed greater declines in eCC with LPV/r ? TDF/3TC compared with EFV ? TDF/3TC [45] . Greater declines in eCC at 96 weeks were also observed in the LPV/ r ? TDF/FTC arm versus the LPV/r ? raltegravir (RAL) arm in PROGRESS (ClinicalTrials.gov #NCT00711009), with a larger proportion of patients in the LPV/r ? RAL arm shifting to a better CKD category at 96 weeks [46] . Similarly in ACTG A5208, events of renal insufficiency were higher in the LPV/r ? TDF/FTC arm versus the nevirapine (NVP) ? TDF/FTC arm, a finding that was confirmed on multivariate analyses [47] . These findings suggest a similar conclusion to that described for ATV/r, namely an interaction between LPV/r and TDF, especially since the post hoc ACTG A5142 analysis identified relevant drug transporter polymorphisms in whose presence TDF exposures may be increased by LPV/r inhibition of these transporters [45] .
Treatment-Experienced Patients
In six out of the seven treatment-experienced studies identified, there were no changes to the PI component of the regimen; thus, it was not possible to assess the contribution of the PI component to changes in eGFR or eCC in these studies [48] [49] [50] [51] [52] [53] .
In an open-label, randomized trial in treatment-experienced patients receiving highly active ARV therapy (HAART) for at least 6 months [the KITE study (ClinicalTrials.gov #NCT00700115)], patients were randomized to switch to RAL ? LPV/r (n = 40) or to remain on their pre-existing HAART regimen (n = 20) [54] . At baseline, there were no statistically significant differences in regimen components between groups with approximately 40% receiving LPV/r, 20% receiving other PIs, 40%
an NRTI and 60% TDF; however, baseline eCC (CG equation) was significantly higher in the RAL ? LPV/r group. Mean eCC at 48 weeks adjusted for baseline value was 106.1 in the RAL ? LPV/r group versus 115.9 mL/min in the continuing HAART group (mean difference 9.7 mL/min; 95% CI -4.7, 24.2; P = 0.18).
Study limitations included open-label design, small sample size, baseline imbalance in eCC between groups, and the high proportion of patients continuing on a PI in the HAART group making changes in eCC consequent to switching to RAL ? LPV/r difficult to interpret. In summary, although adjusted mean eCC was numerically higher in the continuing HAART versus the RAL ? LPV/r group, absolute values for eCC were higher in the RAL ? LPV/r group by virtue of the imbalance in baseline eCC between the two groups. In addition, the adjusted mean difference was not significant.
It is, therefore, unlikely that the switch to LPV/r was associated with meaningful changes in kidney function.
Observational Cohort Studies
Owing to the wide variety of study designs and outcome measures employed, it was not possible to meaningfully tabulate the observational cohort studies. A summary description of these studies is provided as follows. Patients with prior but not current ATV or LPV/r exposure did not have an increased incidence of CKD compared with those with no prior exposure to ATV or LPV/r, whereas patients discontinuing TDF continued to have a significantly increased incidence of CKD for up to 12 months after discontinuation (see web figure one b in Mocroft et al. [60] ). The authors concluded that changes in kidney function with LPV/r and ATV were generally reversible on cessation of these PIs.
Treatment-Naïve Patients
In As the eCC declined, rates of switching from ATV/r, LPV/r, and TDF increased, but this was especially the case for TDF (Fig. 2) . After adjustment, those exposed, but currently off TDF, had similar IRRs for advanced CKD compared to those unexposed, while those currently on TDF had reduced rates (note: that those with reduced eCC while on TDF were more likely to discontinue). None of the other ARV drugs included in the analysis showed a significant effect on IRRs for CKD/ESRD. However, the adjusted IRR of CKD/ESRD was increased with diabetes, hypertension, lower baseline eGFR, and decreased in those who had >90 
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Adjusted incidence rate ratio (95% CI) of ARV discontinuation Participants with HIV infection initiating TDF in combination with a PI-or NNRTI-based regimen were assessed in a large cohort study (NA-ACCORD), reported as an abstract [64] . and older in age (P = 0.03); given that both factors are associated with a higher risk of CKD, the clinical significance of changes in renal function in this study cannot be determined.
In a prospective study using data from the Swiss HIV Cohort Study database, patients were identified who were ARV-naïve or whose ARV therapy had been interrupted for C12 months (n = 1,078) [65] . Selected patients were required to have a baseline eCC (CG equation) and at least two eCC values after starting or restarting combination ARV therapy. The authors stated that the CG equation was preferred over the AE adverse event, ATV/r ritonavir-boosted atazanavir, DRV/r ritonavir-boosted darunavir, EFV efavirenz, FPV/r ritonavirboosted fosamprenavir, GFR glomerular filtration rate, INSTI integrase strand inhibitor, LPV/r ritonavir-boosted lopinavir, NNRTI non-nucleoside(nucleotide) reverse-transcriptase inhibitor, NVP nevirapine, PI protease inhibitor, RAL raltegravir, RPV rilpivirine, SQV/r ritonavir-boosted saquinavir, TDF tenofovir disoproxil fumarate (n = 2,588) [6] . Across the study cohort, the overall prevalence of renal impairment was very high at 39%; mild, moderate, severe, and ESRD were present in 34.2%, 4.4%, 0.3%, and, 0.2% of patients, respectively. In logistic regression models, increasing duration of TDF exposure was associated with an increased risk of mild cases per 100 patient-years. In univariate Poisson regression analysis, ever having been exposed to a PI was associated with an increased incidence of CKD (IRR 3.0; 95% CI 1.5, 5.7; P = 0.008). In multivariate analyses, an independent effect of PIs was no longer evident, but exposure to a PI in combination with TDF for at least 6 months appeared to increase the incidence of CKD [IRR for TDF without PI for C6 months 1.8 (95% CI 1.0, 3.3)
vs. IRR for TDF with PI for C6 months 3.5 (95% CI 2.1, 6.1); P value for difference = 0.0006].
Other associated risk factors were ever having been exposed to TDF (IRR 2.5; 95% CI 1.5, 4.1; P = 0.0002), female gender, older age, low baseline eGFR, diabetes, hyperlipidemia, and low CD4 count. However, the median exposure to PIs (3.6 years) was longer than that for TDF Taken together, the RCT data would suggest little evidence for an independent effect of PIs on decline in renal function, especially since studies examining changes in proteinuria with PIs without concomitant TDF use have shown no change in proteinuria with treatment [67, 68] . Evidence for an interactive effect of PIs with TDF on initial but non-progressive declines in eGFR was consistent and was demonstrated across ATV and LPV; however, few studies conducted multivariate analyses and of those that did, three showed that the PI effect remained significant after adjustment [39, 40, 47] and the fourth that it was no longer significant [44] . Regarding a potential mechanism for this PI-TDF interaction, the post hoc ACTG A5142 analysis suggested that LPV/r inhibition of drug transporters may increase TDF exposures [45] . It should also be noted that most RCTs excluded patients with baseline eGFR\70 mL/min, and that only one were not, however, associated with the development of advanced CKD or ESRD [62] ; discontinuation analyses by current eGFR level suggested that TDF discontinuation may protect against the development of advanced CKD/ ESRD in these patients. Data from other cohorts provided conflicting conclusions as to whether the increased risk of CKD was attributable to an independent effect of PIs as suggested in the Swiss Cohort study [65] or only in interaction with TDF as suggested in the CO3 Aquitaine Cohort study [66] . an increase in eGFR in ACTG 5224s [67] and in another study [44] . This systematic review has a number of strengths. To our knowledge, this represents the most comprehensive review of the potential association of PIs with CKD undertaken. We attempted to summarize all available RCT data and, in order to reduce bias from small observational studies or case series, pre-defined criteria were established to select only those observational studies least likely to be subject to bias. We also structured our evaluation using the OCEBM levels of evidence criteria to allow readers to easily assess the strength of available evidence.
A number of limitations, inherent to the nature of the data being evaluated, were also noted. The available data on CKD were heavily influenced by year of introduction of ARVs, which could introduce bias; thus, many RCTs and cohort studies were identified using ATV/r or LPV/r, but only a single small RCT using DRV/r.
RCT data should have been less subject to bias owing to the process of randomization; however, many of these trials were of small sample size, of short duration (48 weeks 
